Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
Status:
Recruiting
Trial end date:
2023-08-25
Target enrollment:
Participant gender:
Summary
This is a Phase 2 study in patients with chronic obstructive pulmonary disease (COPD) to
assess the efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and safety of two dose
levels of CSJ117 in comparison to placebo. For this, the impact of CSJ117 on disease symptom
burden and lung function will be explored.